Analysis of Antibody Drug Conjugates

As biopharmaceutical organizations explore the use of Antibody Drug Conjugates (ADC) as a class of cancer therapies, significant challenges are found in analyzing their complex, heterogeneous structures. The determination of drug-to-antibody ratios (DAR) and sites of conjugation presents unique analytical challenges that can be addressed with Waters' fit-for-purpose UPLC, QTof MS, and informatics solutions.